Skip to main content

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Alliance Foundation Trials, LLC

Start Date

November 17, 2017

End Date

April 30, 2023
 

Administered By

Duke Cancer Institute

Awarded By

Alliance Foundation Trials, LLC

Start Date

November 17, 2017

End Date

April 30, 2023